Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 13/20 | 0.44 |
| ▸ | IGF1R | P08069 | 4/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | AKT2 | P31751 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3352543 | 0.97 | HDAC1 (0.45) | HDAC1IGF1RAKT1AKT2EGFR | |
| SCHEMBL198043 | 0.94 | HDAC1 (0.43) | HDAC1IGF1REGFRERBB2 | |
| SCHEMBL3351761 | 0.93 | HDAC1 (0.44) | HDAC1AKT1AKT2BRD4JAK1 | |
| SCHEMBL3353147 | 0.90 | HDAC1 (0.45) | HDAC1AKT1AKT2BRD4JAK1 | |
| SCHEMBL3354346 | 0.89 | HDAC1 (0.43) | HDAC1AKT1AKT2 | |
| SCHEMBL3352234 | 0.89 | HDAC6 (0.36) | HDAC1IGF1RAKT1AKT2EGFR | |
| SCHEMBL3352038 | 0.88 | HDAC1 (0.48) | HDAC1BRD4JAK1 | |
| SCHEMBL3357301 | 0.88 | HDAC1 (0.43) | HDAC1 | |
| SCHEMBL3352678 | 0.88 | HDAC1 (0.45) | HDAC1 | |
| SCHEMBL197347 | 0.87 | HDAC1 (0.43) | HDAC1AKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198299-B2 | Cycloalkylidene and heterocycloalkylidene inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-06-12 | — | — | US | claimed |
| US-20100022543-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-01-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022543-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC2 | HDAC1 1/4885IGF1R 1912/4885AKT1 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.